Le Lézard
Classified in: Health, Business
Subject: CON

Department of Veterans Affairs to Provide New Treatment Options for Veterans Suffering from Major Depressive Disorder


MORRISVILLE, N.C., Oct. 17, 2017 /PRNewswire/ -- Magstim, a pioneer in the study and development of Transcranial Magnetic Stimulation (TMS), has received a contract from the Veterans Administration to help treat Major Depressive Disorder (MDD) in Veterans who have failed to achieve satisfactory improvement from prior antidepressant medication.

TMS focuses magnetic pulses to brain cells to help treat Major Depressive Disorder.

TMS is a non-invasive procedure that employs magnetic fields to stimulate nerve cells in the brain to reduce symptoms of depression. The device has been approved by the Food and Drug Administration (FDA) whose indication statement describes TMS as "an effective therapy for adults with MDD who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode."

The RAND Center for Military Health Policy Research says 300,000 (~20%) of the 1.7 million Veterans who served in Iraq and Afghanistan suffer from post-traumatic stress disorder or major depression. It has been estimated that 14% experience depression after deployment ? though the percentage is almost certainly higher because many Veterans don't seek care. In addition, active military service members are particularly susceptible. The same research indicates 19% have experienced traumatic brain injuries during combat which can also trigger depressive symptoms.

TMS is performed in a doctor's office or clinic with the patient seated in a comfortable chair while a "coil" is placed against the head. A series of repetitive, brief and highly-focused magnetic pulses are emitted to stimulate brain cells and, in depressed patients, restore brain activity to normal levels. Treatment sessions last less than 45 minutes and are typically performed five days per week, over a six-week period.

Magstim's TMS therapy is non-invasive and has very few side effects.  Lothar Krinke, PhD, Group CEO at Magstim, says, "We are delighted to have this opportunity to employ Magstim TMS systems to increase patient access to treatment and improve health outcomes for Veterans. We are committed to working with the Department of Veterans Affairs as they move the field of psychiatric care forward."

Contact:
Alan Zachary
[email protected]
708/707-6834

Magstim Logo

SOURCE Magstim


These press releases may also interest you

at 17:30
The global insurance market size is estimated to grow by USD 1.42 billion from 2023-2027, according to Technavio. The market is estimated to grow at a CAGR of 4.5% during the forecast period. ...

at 17:25
MedMen Enterprises Inc. ("MedMen" or the "Company"), a cannabis company with subsidiaries operating across the United States, today announced that it made an assignment into bankruptcy pursuant to Canada's Bankruptcy and Insolvency Act (the...

at 17:21
Coffee for the Troops returns with its 22nd round of celebrating our troops! This biannual campaign kicks off Saturday, April 27th and runs through Monday, May 27th. During this time, customers at Books-A-Million and 2nd & Charles are invited to...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...

at 17:08
New York Community Bancorp, Inc. (the "Company") today announced that Wednesday, June 5th, has been established as the new date of its 2024 Annual Meeting of Shareholders....

at 17:02
Intercorp Financial Services Inc. ("IFS" or the "Company") (BVL/NYSE: IFS) announced today the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2023 (the "2023 Annual Report") with the U.S. Securities and Exchange...



News published on and distributed by: